Several healthcare reform proposals culminated in the enactment of the Inflation Reduction Act of 2022 (“IRA”) for example, contains substantial drug pricing and other reforms to Medicare’s coverage of pharmaceuticals. Among other things, the IRA eliminated, beginning in 2025, the coverage gap under Medicare Part D by significantly lowering the enrollee maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program (replacing the former Coverage Gap Discount Program), 10% of Part D enrollees’ prescription costs for brand drugs below the out-of-pocket limit, and 20% once the out-of-pocket limit has been reached.
All entries for: Dermatology
March 30, 2026
Veradermmics, Inc
Neutral Outlook
New Haven, CT
1-50 employees
For example, the Inflation Reduction Act of 2022, or the IRA, which is having a significant and ongoing impact on the pharmaceutical industry, includes a number of changes intended to address rising prescription drug prices in Medicare Parts B and D, such as caps on Medicare Part D out-of-pocket costs and a drug price negotiation program for certain high-spend Medicare Part B and D drugs.
Disease Area: Dermatology
Drug Type: Small Molecule
March 26, 2026
Journey Medical Corp
Neutral Outlook
Scottsdale, AZ
51-200 employees
The Inflation Reduction Act of 2022 (the “IRA”) contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services (“HHS”) that would require manufacturers to charge a negotiated “maximum fair price” for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs.
Disease Area: Dermatology
Drug Type: Small Molecule
March 26, 2026
Quoin Pharmaceuticals, Ltd.
Neutral Outlook
Ashburn, VA
1-50 employees
The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. These provisions have been and may continue to be subject to legal challenges. It is unclear what policies will be advanced with respect to IRA implementation and other drug pricing proposals.
Disease Area: Dermatology, Rare Diseases
Drug Type: Biologic, Small Molecule
March 23, 2026
Avalo Therapeutics
Neutral Outlook
Wayne, PA
1-50 employees
The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA’s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known.
Disease Area: Chronic Disease, Dermatology, Immune Diseases
Drug Type: Biologic, Small Molecule
March 19, 2026
Sol-Gel Technologies Ltd
Neutral Outlook
Whippany, NJ
1-50 employees
In August 2022, the Inflation Reduction Act, or IRA, was signed into law. The IRA includes multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States. For example, a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the product’s price increases faster than the rate of inflation.
Disease Area: Dermatology, Oncology, Rare Diseases
Drug Type: Small Molecule
March 19, 2026
Pelthos Therapeutics
Negative Outlook
Durham, NC
51-200 employees
In addition, the Inflation Reduction Act of 2022 (“IRA”) which among other things, extended enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminated the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have an adverse effect on customers for ZELSUVMI and our product candidates, if approved, and, accordingly, our financial operations.
Disease Area: Dermatology, Infectious Diseases
Drug Type: Small Molecule
March 18, 2026
Vyome Holdings
Neutral Outlook
Cambridge, MA
1-50 employees
Further, judicial challenges to the IRA may have an impact on the implementation of the IRA’s provisions; and the overall effects of the IRA on Bio’s business and the healthcare industry in general is not yet known.
Disease Area: Dermatology, Immune Diseases
Drug Type: Small Molecule
March 13, 2026
Nektar Therapeutics
Neutral Outlook
San Francisco, CA
51-200 employees
Although the effects of the IRA on our business and the healthcare industry in general are not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
Disease Area: Dermatology, Endocrinology, Immune Diseases, Neurological Diseases, Oncology
Drug Type: Biologic